CE Mark for Symmetry vagus nerve stimulation therapy to treat depression. - LivaNova PLC
Related news and insights
Axsome Therapeutics Inc. in its second quarter statement said the FDA has raised deficiencies related to the company's AXS-05 new drug application that could delay approval of the proposed treatment of major depressive disorder.
Sage Therapeutics, Inc. and Biogen Inc. announced that the WATERFALL Study in patients with MDD met its primary endpoint with zuranolone (SAGE-217/BIIB125) 50 mg showing statistically significant improvement in depressive symptoms compared with placebo at Day 15 as assessed by the 17-item Hamilton Rating Scale for Depression (HAMD-17) total score.